C1orf189 Inhibitors
C1orf189 inhibitors encompass a range of chemical compounds that act through various biochemical mechanisms to reduce the functional activity of C1orf189. For instance, PD 0332991, a selective inhibitor of CDK4/6, leads to cell cycle arrest at the G1 phase, which is a critical control point where C1orf189 is presumed to play a role. This results in a direct decrease in C1orf189 activity associated with cell cycle progression. Similarly, Rapamycin targets mTOR signaling, a pathway that is crucial for cellular growth and proliferation, and its inhibition would result in a decreasein C1orf189's involvement in these processes. Imatinib, by inhibiting BCR-ABL and other tyrosine kinases, potentially affects signaling pathways where C1orf189's function is relevant, leading to a reduction of its activity due to the disruption of upstream kinase activity. Trichostatin A's inhibition of histone deacetylases can repress gene expression patterns that possibly include C1orf189, thereby reducing its functional involvement in the cell.
In addition to these, compounds such as LY 294002 and Curcumin target the PI3K/Akt and NF-κB pathways, respectively. LY 294002's inhibition of PI3K/Akt signaling can result in diminished activity of C1orf189 if it is reliant on this pathway for its functional role. Curcumin's suppression of NF-κB may decrease C1orf189 activity by impacting the transcription factors that regulate its expression or function. Thalidomide and Bortezomib interfere with protein stability through modulation of the ubiquitin-proteasome system, potentially leading to a decreased function of C1orf189 if it depends on the stability of specific regulatory proteins. Additionally, inhibitors like Staurosporine, Sodium Butyrate, PD 98059, and SP600125 act on various kinases and signaling molecules, leading to the indirect inhibition of C1orf189 by altering the phosphorylation state and gene expression patterns related to its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991, a CDK4/6 inhibitor, impedes cell cycle progression. Given that C1orf189 is implicated in cell cycle regulation, inhibition of CDK4/6 by Palbociclib would arrest the cell cycle, thereby diminishing C1orf189's functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, suppresses the mTOR pathway. Since C1orf189 is associated with growth signaling, the inhibition of the mTOR pathway by Rapamycin leads to a reduction in C1orf189 activity related to cellular growth processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib, a BCR-ABL tyrosine kinase inhibitor, also impacts other kinases. If C1orf189 is part of a signaling cascade that includes tyrosine kinase activity, Imatinib would diminish its activity by inhibiting upstream kinase signaling. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, alters chromatin structure and gene expression. By reshaping the epigenetic landscape, Trichostatin A can diminish C1orf189 activity if its function is contingent on specific gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002, a PI3K inhibitor, diminishes PI3K/Akt pathway signaling. C1orf189, if it relies on PI3K/Akt for its activity, would have decreased function upon inhibition of this pathway by LY294002. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin, a compound with multiple targets, is known to inhibit NF-κB signaling. If C1orf189's activity is enhanced by NF-κB, then curcumin would lead to the functional diminishment of C1orf189. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide, a modulator of the ubiquitin-proteasome pathway, could lead to the degradation of proteins associated with cellular signaling. This action may result in decreased C1orf189 activity if it is stabilized by such proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, could diminish C1orf189 activity indirectly by altering the degradation of signaling proteins that regulate C1orf189's function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, could indirectly diminish C1orf189 activity by inhibiting kinases that phosphorylate proteins in the same pathway as C1orf189. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium Butyrate, an HDAC inhibitor, could diminish the activity of C1orf189 by altering gene expression and chromatin structure, thereby affecting the protein's function if it is regulated by such epigenetic modifications. | ||||||